Stock·NYSE·Healthcare
Cigna Corp (CI)
- Market cap
- $79.94B
- P/E
- 12.05
- Dividend yield
- 2.05%
- Street target
- $345.00median of 24 analysts
- 52-week range
- $239.51 $311.34
The short version
Where CI stands today, in four lines, and what CleaRank Financial AI makes of it.
CI at a glance
Cigna Corp (CI): Strong Buy, 82/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($278.92 and $280.43).
- Earnings CI beat estimates in 3 of its last 3 quarters, yet fell the next day after 2 of those beats.
- Insiders Insiders sold $77.0M and bought $1,000K over the last 18 months.
- Valuation P/E of 12.1 against 31.9 for the Healthcare sector: a discount to peers (-62%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Cigna Corp (CI) Strong Buy, with a model score of 82/100.
The trend lifts the score most: the price is 7.80% above its 200-day average and 8.38% above its 50-day average. The 50-day average stands at $278.92 and the 200-day at $280.43. Over the past year the price rose 3.93%.
Only on CleaRank
Figures we compute ourselves from CI's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $302.30 is 8.4% above the 50-day simple moving average of $278.92.Price above its 200-day average ›
The price is 7.8% above the 200-day simple moving average of $280.43.50-day average above the 200-day ›
The 50-day average ($278.92) is 0.5% below the 200-day average ($280.43), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 87% of its 52-week range, between $239.51 and $311.34.
CI share price
Pick a period: each tab shows how far CI has moved over it, to the last close.
Today's trading
Where CI sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 12.05 is 62.2% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 0.28 is 91.8% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $6.4B on revenue of $282.4B, a net margin of 2.3%.Beat estimates in most recent reports ›
CI beat the EPS estimate in 3 of its last 3 reports.Pays a dividend ›
The trailing dividend yield is 2.05%, or $6.19 a share a year.
Key statistics
The headline figures for CI.
As of October 17, 2026, CI trades at $302.30, with a market value of $79.94B, a P/E ratio of 12.05 and a dividend yield of 2.05%.
What the numbers say
CleaRank Financial AI's reading of CI's valuation, growth and risks.
Priced at 12.05 times trailing earnings, Cigna Corp (CI) sits 62.2% below the Healthcare median of 31.9, a P/E the peer comparison on this page rates as a discount to peers. The price-to-sales ratio of 0.28 sits 91.8% below the sector median of 3.4. CI has a market capitalisation of $79.9B and trailing earnings of $24.79 a share.
CI's revenue grew 6.70% in the latest year, a pace that trails the sector median of 8.1%. The company converts that revenue into a net margin of 2.27% and an operating margin of 3.99%. Its return on equity of 16.76% sits above the sector median of 7.3%. On the balance sheet, debt-to-equity stands at 0.74, and the trailing dividend yield is 2.05%, equal to $6.19 a share a year.
In the most recent available report in our data, dated February 5, 2026, CI beat the estimate by 2.54%, posting EPS of $8.08 versus an estimate of $7.88. Investors responded positively, and the stock rose 2.64% in the next session.
Across its last 3 reports, CI has come in above the EPS estimate every time, yet the share price fell in the first session after 2 of those 3 beats. For this fiscal year, analysts expect EPS of $30.51, a change of 2.2%. Next year's average estimate is $33.48, which would be growth of 9.7%.
The 30-day standard deviation of CI's daily returns is 1.53%.
CI against the Healthcare sector
How CI compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: CI trades at a notable discount to sector peers (-62%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 6, 2025, CI has lost 9.4% against a gain of 31.4% for XLV.
Performance against XLV
CI and the Healthcare sector fund over the same days.
Revenue and earnings
How much CI sells, and how much of it becomes profit.
Revenue growth: Revenue grew 12.1% in FY2025 to $274B, from $244B a year earlier.
Profit margin: The net margin was 2.3% in FY2025, up from 1.5% the year before.
Profitable: CI earned $6.3B in FY2025.
Earnings reality check
Did CI beat what analysts expected, and how did the stock react?
Earnings record: CI beat the analyst estimate in 3 of the last 3 quarters.
Market reaction: The stock fell in the first session after 2 of those 3 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Feb 5, 2026after close | $7.88 | $8.08 | +2.54% | +2.64% | +1.08% |
| Jul 31, 2025after close | $7.15 | $7.20 | +0.70% | -1.93% | +1.35% |
| May 2, 2025after close | $6.35 | $6.74 | +6.14% | -0.52% | -0.39% |
Reports after February 5, 2026 are not yet in our data.
As of October 17, 2026, CI has beaten the analyst EPS estimate in 3 of its last 3 reported quarters and fell in the first trading session after 2 of those beats; its most recent report in our data, on February 5, 2026, came in 2.54% above the estimate and the stock moved +2.64% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 73.2, in overbought territory.RSI above 50 ›
An RSI of 73.2 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of CI
The score, the reasoning behind it, and what could move the price next.
Cigna Corp (CI) is in an uptrend. The price of $302.30 stands 7.80% above its 200-day average of $280.43 and 8.38% above its 50-day average of $278.92. Near the top of its 52-week range, the price is 2.90% below the high of $311.34 and 26.22% above the low of $239.51. The averages are still catching up with the price, since the 50-day sits 0.54% below the 200-day.
CI's 14-day RSI of 73.2 places it in overbought territory, while the MACD line is positive. Price performance points the same way across every window shown: the stock is up 7.49% over three months, 8.57% over six months and 3.93% over the past year.
Earnings beat ›
The February 5, 2026 report beat the EPS estimate by 2.54%, and the share price rose 2.64% in the first session after it.
Source: Earnings report, February 5, 2026
Analyst downgrade ›
Jefferies downgraded it to Hold from Buy on August 4, 2026.
Source: Analyst action, Jefferies, August 4, 2026Analyst downgrade ›
Raymond James downgraded it to Outperform from Strong Buy on August 3, 2026.
Source: Analyst action, Raymond James, August 3, 2026
- Two levels matter most right now: the 52-week high at $311.34, which sits above the price, and the 20-day EMA at $282.45, which sits below it.
- The 14-day RSI reads 73.2, which is overbought, while the MACD line is positive. Readings above 70 or below 30 point to stretched momentum.
- CI beat estimates in 3 of the last 3 reports. After the February 5, 2026 report, the share price rose 2.64% in the first session.
CI's uptrend depends on the price holding above its 50-day average of $278.92 and its 200-day average of $280.43. A close below the 200-day average would be the first sign that the trend is weakening. If the price pulls back, the first level it would reach is the 20-day EMA at $282.45.
Cigna Corp (CI) has its next resistance at the 52-week high of $311.34. With the RSI above the overbought line, a pause in momentum would be normal even while the uptrend holds.
Technical indicators
Momentum and trend for CI, from its daily closes.
As of October 17, 2026, with CI at $302.30, its 14-day RSI is 73.2 (overbought territory), its 50-day simple moving average is $278.92 and its 200-day is $280.43.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What CI moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, CI's 1-year correlation of daily returns is +0.07 with S&P 500 (SPY), -0.03 with Nasdaq 100 (QQQ), -0.02 with Bitcoin (BTC) and -0.01 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
18 of 24 analysts rate it a buy or strong buy, 6 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $345.00 is 14.1% above the price.More buy ratings than three months ago ›
18 of 24 rate it a buy now, against 20 of 24 three months ago.
CI Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 2, 2026 | Piper Sandler | Maintains | Overweight |
| Oct 1, 2026 | RBC Capital | Reiterates | Outperform |
| Aug 4, 2026 | Jefferies | Downgrade | Hold |
| Aug 3, 2026 | Raymond James | Downgrade | Outperform |
| Jul 31, 2026 | Wells Fargo | Maintains | Equal-Weight |
| Jul 31, 2026 | Guggenheim | Maintains | Buy |
As of October 17, 2026, 24 Wall Street analysts cover CI: 18 rate it a buy or strong buy, 6 a hold and 0 a sell or strong sell. Their 12-month price targets range from $288.00 to $400.00, with a median of $345.00, 14.1% above the price of $302.30.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CI trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CI's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CI tends to move, against the market and on its own.
The long record
CI's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.53% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 34.4%, from November 2018 to May 2019, regained by March 2021.Most 1-year holds ended higher ›
65% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $28,337, against $42,055 in the S&P 500 (SPY).
CI Drawdowns & Recovery
As of October 17, 2026, CI's worst peak-to-trough fall over the last 10 years with dividends reinvested was -34.4% (November 2018 to May 2019); it regained that peak by March 2021, 22 months after the low, and 65% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CI in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CI trailed the S&P 500 over this period: $28,337 against $42,055.
A $10,000 investment in CI in October 2016 would be worth about $28,337 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CI, and which have not.
Strongest month, October: an average of +5.87%, up in 7 of 9 years.
Weakest month, March: an average of -3.62%, up in 4 of 10 years.
This month, October: has averaged +5.87%, up in 7 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CI's strongest calendar month has been October (average +5.87%, up in 7 of 9 years) and its weakest March (average -3.62%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CI, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CI today could grow to about $20,957 by 2036 in the base case, with a 90th-percentile outcome near $73,295 and a 10th-percentile outcome around $5,992. The simulation models price only; at today's 2.05% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
CI Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $406 for CI by 2030 in the base case, from $302 today (1.3x over 4 years). The 10th-percentile path ends near $184. These are outcomes of a Monte Carlo simulation run on CI's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $219 | $326 | $484 | |
| 2028 | $200 | $351 | $614 | |
| 2029 | $190 | $377 | $749 | |
| 2030 | $184 | $406 | $897 | |
| 2031 | $181 | $438 | $1,061 |
Method: a lognormal simulation of CI's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
CI insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $1,000K on the open market and sold $77.0M.
As of October 17, 2026, CI insiders reported 9 open-market sales worth $77.0M and 1 open-market purchase worth $1,000K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Everett Neville
Officer
|
Sell | 617 | $175.3K |
| Sep 1, 2026 | Brian C Evanko
Chief Executive Officer
|
Grant | 3.1K | - |
| Aug 18, 2026 | Nicole S. Jones
Officer
|
Sell | 2.7K | $748.5K |
| Aug 5, 2026 | Nicole S. Jones
Officer
|
Option | 15.3K | $2.9M |
| Aug 4, 2026 | Nicole S. Jones
Officer
|
Sell | 19.4K | $5.4M |
| Jun 12, 2026 | Jamie G Kates
Officer
|
Sell | 899 | $268.5K |
| Jun 12, 2026 | Jamie G Kates
Officer
|
Option | 899 | $137.5K |
| May 13, 2026 | David M Cordani
Chief Executive Officer
|
Option | 212.5K | $36.2M |
| May 12, 2026 | David M Cordani
Chief Executive Officer
|
Sell | 201.9K | $59.1M |
| Apr 22, 2026 | Eric J. Foss
Director
|
Grant | 782 | - |
| Apr 22, 2026 | Neesha Hathi
Director
|
Grant | 782 | - |
| Apr 22, 2026 | Michael J Hennigan
Director
|
Grant | 782 | - |
| Apr 22, 2026 | George Kurian
Director
|
Grant | 782 | - |
| Apr 22, 2026 | Kathleen M. Mazzarella
Director
|
Grant | 782 | - |
| Apr 22, 2026 | Mark B Mcclellan
Director
|
Grant | 782 | - |
| Apr 22, 2026 | Phillip Ozuah
Director
|
Grant | 782 | - |
| Apr 22, 2026 | Kimberly A Ross
Director
|
Grant | 782 | - |
| Apr 22, 2026 | Eric C Wiseman
Director
|
Grant | 782 | - |
| Apr 22, 2026 | Donna F Zarcone
Director
|
Grant | 782 | - |
| Mar 2, 2026 | Nicole S. Jones
Officer
|
Sell | 2.3K | $666.5K |
| Mar 2, 2026 | Everett Neville
Officer
|
Sell | 1.7K | $496.6K |
| Feb 27, 2026 | David M Cordani
Chief Executive Officer
|
Grant | 41.2K | - |
| Feb 27, 2026 | Ann M Dennison
Chief Financial Officer
|
Grant | 5.2K | - |
| Feb 27, 2026 | Brian C Evanko
Officer
|
Grant | 16.2K | - |
| Feb 27, 2026 | Nicole S. Jones
Officer
|
Grant | 9.4K | - |
| Feb 27, 2026 | Jamie G Kates
Officer
|
Grant | 814 | - |
| Feb 27, 2026 | Durga Prasad Koka
Officer
|
Grant | 3.2K | - |
| Feb 27, 2026 | Everett Neville
Officer
|
Grant | 5.3K | - |
| Nov 3, 2025 | David M Cordani
Chief Executive Officer
|
Buy | 4.1K | $999.9K |
| Oct 6, 2025 | Brian C Evanko
President
|
Option | 6.3K | $872.8K |
| Oct 3, 2025 | Brian C Evanko
President
|
Sell | 5.4K | $1.6M |
| Aug 18, 2025 | Nicole S. Jones
General Counsel
|
Option | 27.4K | $5.2M |
| Aug 15, 2025 | Nicole S. Jones
General Counsel
|
Sell | 28.5K | $8.6M |
| Jun 2, 2025 | Michael J Hennigan
Director
|
Grant | 568 | - |
| Apr 23, 2025 | Eric J. Foss
Director
|
Grant | 638 | - |
| Apr 23, 2025 | Elder Granger
Director
|
Grant | 638 | - |
| Apr 23, 2025 | Neesha Hathi
Director
|
Grant | 638 | - |
| Apr 23, 2025 | George Kurian
Director
|
Grant | 638 | - |
| Apr 23, 2025 | Kathleen M. Mazzarella
Director
|
Grant | 638 | - |
| Apr 23, 2025 | Mark B Mcclellan
Director
|
Grant | 638 | - |
| Apr 23, 2025 | Phillip Ozuah
Director
|
Grant | 638 | - |
| Apr 23, 2025 | Kimberly A Ross
Director
|
Grant | 638 | - |
| Apr 23, 2025 | Eric C Wiseman
Director
|
Grant | 638 | - |
| Apr 23, 2025 | Donna F Zarcone
Director
|
Grant | 638 | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.